- Home
- OMER vs CCBG Comparison
OMER vs CCBG Comparison
Compare OMER & CCBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMER | CCBG |
|---|---|---|
| Founded | 1994 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.9M | 726.2M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | OMER | CCBG |
|---|---|---|
| Price | $12.52 | $43.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $32.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 4.4M | 65.1K |
| Earning Date | 11-13-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 2.39% |
| EPS Growth | N/A | ★ 17.47 |
| EPS | N/A | ★ 3.57 |
| Revenue | N/A | ★ $246,433,000.00 |
| Revenue This Year | N/A | $12.46 |
| Revenue Next Year | N/A | $3.24 |
| P/E Ratio | ★ N/A | $12.19 |
| Revenue Growth | N/A | ★ 9.03 |
| 52 Week Low | $2.95 | $32.38 |
| 52 Week High | $17.65 | $45.63 |
Technical Indicators
Market Signals| Indicator | OMER | CCBG |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 56.86 |
| Support Level | $11.85 | $41.96 |
| Resistance Level | $16.14 | $44.63 |
| Average True Range (ATR) | 1.62 | 0.92 |
| MACD | -0.37 | -0.06 |
| Stochastic Oscillator | 43.31 | 57.54 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.